Hypersulfated disaccharides and methods of using the same for the treatment of inflammations
Provided are compounds and compositions thereof that are useful for treating inflammation, particularly pulmonary inflammations including asthma and asthma-related pathologies such as allergy. Also provided are methods for using such compounds and compositions of the invention to treat patients suffering from, or predisposed to develop inflammation.
1. A compound of Structure I, comprising:
wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are either SO 3 − , PO 3 − or H; and
(a) wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are each independently either SO 3 − , PO 3 − or —H; and
(b) wherein at least five of the group consisting of R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are each independently either SO 3 − or PO 3 − ; or
(c) wherein at least four of the group consisting of R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are each independently either SO 3 − or PO 3 − ; or
(d) wherein at least three of the group consisting of R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are each independently either SO 3 − or PO 3 − ; and
provided that, if
(i) R 3 arid R 4 are both SO 3 − then at least one of the group consistig of R 1 , R 2 , R 5 , and R 6 are either SO 3 − or PO 3 − ; or
(ii) R 3 , R 4 , R 5 are SO 3 − then at least one of the group consisting of R 1 , R 2 , R 6 are either SO 3 − , or PO 3 − , or
(iii) R 1 and R 4 are both SO 3 − and R 3 is not SO 3 − , then at least one of the group consisting or R 2 ,R 5 , and R 6 are either SO 3 − , or PO 3 − .
2. The compound according to claim 1 , selected from the group consisting of the compounds having structures II–VIII:
3. The compound according to claim 1 , selected from the group consisting of the compounds having structures IX–XV:
4. A compound of Structure XVI, according to claim 1 , comprising:
wherein R 1 , R 3 , R 4 , R 5 , and R 6 are each independently either SO 3 − or PO 3 − .
5. A pharmaceutical composition for treating or alleviating the symptoms of inflammatory and allergic pulmonary reactions in a mammalian patient comprising a therapeutically effective amount of the compound of Structure I in a pharmacutically acceptable vehicle:
wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are either SO 3 − , PO 3 − or H; and
(a) wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are each independently either SO 3 − , PO 3 − or —H; and
(b) wherein at least five of the group consistng of R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are each independently either SO 3 − or PO 3 − ; or
(c) wherein at least four of the group consisting of, R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are each independently either SO 3 − or PO 3 − ; or
(d) wherein at least three of the group consisting of R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are each independently either SO 3 − or PO 3 − ; and
and provided that, if
(i) R 3 and R 4 are both SO 3 − then at least one of the group consisting of R 1 R 2 , R 5 , and R 6 are either SO 3 − or PO 3 − ; or
(ii) R 1 and R 4 are both SO 3 − and R 3 is not SO 3 − , then at least one of the group consisting of R 2 , R 5 , and R 6 are either SO 3 − or PO 3 − ;
and further provided that, if only R 3 , R 4 , R 5 are SO 3 − then said pharmaceutical composition is enriched for said compound.
6. The pharmaceutical composition according to claim 5 , comprising at least one of the compounds selected from the group consisting of tile compounds having structures II–VIII:
7. The pharmaceutical conposition according to claim 5 , comprising at least one of the compounds selected from the group consisting of the compounds having structures IX–XV:
8. A pharmaceutical composition according to claim 5 , for treating or alleviating the symptoms of inflammatory reactions in a mammalian patient comprising a therapeutically effective amount of the compound of Structure XVI:
wherein R 1 , R 3 , R 4 , R 5 , and R 6 are each independently either SO 3 − or PO 3 − .
9. The pharmaceutical composition according to claim 5 , comprising from about 0.005 mg to about 1.0 mg per kilogram of patient body weight of said compound having Structure I in each dose.
10. The pharmaceutical composition according to claim 5 , comprising from about 0.075 mg per kilogram of patient body weight to about 0.75 mg per kilogram of patient body weight of said compound having Structure I in each dose.
11. The pharmaceutical composition according to claim 5 , wherein said compound having Strcture I is in an aqueous pharmaceutically acceptable inhalant vehicle.
12. The pharmaceutical composition of claim 9 , further comprising an aerosol propellant and suitable for administration via a metered dose inhaler.
13. The pharmaceutical composition according to claim 5 , comprising a pharmaceutically acceptable powder preparation of said compound having Structure I suitable for intrabronchial administration.
14. The pharmaceutical composition of claim 13 , which is suitable for administration by means of an aerosol dispenser.
15. The pharmaceutical composition according to claim 5 , comprising a pharmaceutically acceptable aqueous preparation of said compound having Structure I suitable for intravenous administration.
16. The pharmaceutical composition according to claim 5 , comprising a pharmaceutically acceptable aqueous preparation of said compound having Structure I suitable for intramuscular administration.
17. A method for treating or alleviating the symptoms of asthma or bronchitis in a mammalian patient, said method comprising the administration to the patient of a pharmaceutical composition comprising a therapeutically effective amount of the compound of Structure I in a pharmaceutically acceptable vehicle:
wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are either SO 3 − , PO 3 − or H; and
a wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are each independentlyeither SO 3 − , PO 3 − or —H;
b wherein at least five of the group consisting of R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are each independently either SO 3 − or PO 3 − ; or
c wherein at least four of the group consisting of R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are each independently either SO 3 − or PO 3 − ; or
d wherein at least three of the group consisting of R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are each independently either SO 3 − or PO 3 − ; and
and provided that, if
i R 3 and R 4 are both SO 3 − then at least one of the group consisting of R 1 , R 2 , R 5 , and R 6 are either SO 3 − or PO 3 − ; or
ii R 1 and R 4 are both SO 3 − and R 3 is not SO 3 − , then at least one of the group consisting of R 2 , R 5 , and R 6 are either SO 3 − or PO 3 − ;
and further provided that, if only R 3 , R 4 , R 5 are SO 3 − then said pharmaceutical composition is enriched for said compound.
18. The method according to claim 17 , wherein the pharmaceutical composition comprises at least one of the compounds selected from the group consisting of the compounds having structures II–VIII:
19. The method according to claim 17 , wherein the pharmaceutical composition comprises at least one of the compounds selected from the group consisting of the compounds having structures IX–XV:
20. The method according to claim 17 , wherein the pharmaceutical composition comprises at least one of the compounds selected from the group consisting of the compounds having structures XVI:
wherein R 1 , R 3 , R 4 , R 5 , and R 6 are each independently either SO 3 − or PO 3 − .
21. The method according to claims 17 , wherein the method is for treating or alleviating the symptoms of asthma.
22. The method according to claim 17 , comprising from about 0.005 mg to about 1.0 mg per kilogram of patient body weight of said compound having Structure I in each dose.
23. The method according to claim 17 , comprising from about 0.075 mg of patient body weight to about 0.75 mg per kilogram patient body weight of said compound having Structure I in each dose.
24. The method according to claim 17 , wherein said compound having Structure I is in an aqueous pharmaceutically acceptable inhalant vehicle.
25. The method according to claim 17 , wherein said administration is by means of a pump or a squeeze-actuated nebulizer.
26. The method according to claim 17 , wherein said administration is via a metered dose inhaler.
27. The method according to claim 17 , wherein said administration is for intrabronchial administration.
28. The method according to claim 17 , wherein said administration is by means of an aerosol dispenser.
29. The method according to claim 17 , wherein said administration is intravenous administration.
30. The method according to claim 17 , wherein said administration is intramuscular administration.